Dermal Fillers Market is Projected to Reach USD 9.30 Billion by 2034; Rising Acceptance of Aesthetic Procedures Across Age Groups and Advancements in Filler Technologies Support Product Demand

The global dermal fillers market size was valued at USD 5.05 billion in 2025. The market is projected to grow from USD 5.33 billion in 2026 to USD 9.30 billion by 2034, exhibiting a CAGR of 7.21% during the forecast period. Fortune Business Insights™ presents this information in its report titled, “Dermal Fillers Market Size, Share & Industry Analysis, By Material (Hyaluronic Acid, Calcium Hydroxyapatite, Poly-L-lactic Acid, PMMA (Poly (Methyl Methacrylate)), Collagen Fillers, and Others), By Product (Biodegradable and Non-Biodegradable), By Application (Scar Correction, Wrinkle and Facial Fold Correction, Facial Volume Restoration and Contouring, and Others), By Gender  (Male and Female), By Age Group  (18-30 Years, 31-45 Years, 46-60 Years, and Above 60 Years), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2026-2034”

Dermal fillers are minimally invasive aesthetic products used to restore facial volume, enhance facial features, and improve the appearance of aging-related concerns. Hyaluronic acid fillers are widely used in this market as they provide temporary and adjustable results across various facial treatment areas. The availability of specialized fillers, advancements in injection technologies, practitioner training, and growing acceptance of aesthetic procedures among different age groups are further supporting the product adoption.

Partnership with IBSA Broadens Evolus’ Presence in Skin-Quality Treatments

In July 2026, the company, Evolus, signed an exclusive licensing and distribution agreement with IBSA for Profhilo in the U.S. Under the agreement, the companies will work on developing and commercializing the product in the country. The partnership allows Evolus to move beyond traditional fillers and enter the expanding skin-quality treatment category.

Rising Demand for Minimally Invasive Procedures Drives Market Expansion

The dermal fillers market growth is driven by the growing preference for minimally invasive cosmetic treatments, increasing the adoption of the products as an alternative to surgical procedures. Their ability to reduce wrinkles, restore facial volume, and enhance facial contours is driving demand for customized treatments across different facial areas. The shift toward subtle, natural-looking results, along with greater access to aesthetic clinics and trained practitioners, is further supporting procedure volumes. In addition, the availability of longer-lasting filler products is expected to contribute to market expansion.

However, the need for repeat treatments, high procedure costs, reliance on trained injectors, and potential risks such as swelling, infection, and tissue damage may limit the use of dermal fillers. 

Regulatory Approvals and Regional Partnerships Strengthen Market Presence

The competitive environment of the market for dermal fillers is moderately consolidated, with leading companies benefiting from well-established injectable product ranges, extensive geographic coverage, and clinical validation. The market participants are also differentiating themselves through specialized hyaluronic acid technologies, cost-effective offerings, regional manufacturing, and expanded practitioner training. Over the forecast period, companies are expected to pursue regulatory approvals in key markets and partner with regional distributors to strengthen their market presence. Product development will also focus on addressing changing facial contours, volume loss following weight reduction, skin hydration, and collagen regeneration.

List of the Companies Profiled in the Report

• Galderma Group AG (Switzerland)
• AbbVie Inc. (U.S.)
• Merz Aesthetics GmbH (Germany)
• TEOXANE SA (Switzerland)
• Sinclair Pharma Limited (U.K.)
• LG Chem, Ltd. (South Korea)
• CROMA-PHARMA GmbH (Austria)
• HUGEL, Inc. (South Korea)
• Prollenium Medical Technologies Inc. (Canada)
• Bloomage Biotechnology Corporation Limited (China)
• Medytox Inc. (South Korea)
• Laboratoires VIVACY, S.A.S. (France)
• IBSA Institut Biochimique SA (Switzerland)
• LABORATOIRES FILLMED (France)
• Evolus, Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/dermal-fillers-market-100939

Notable Industry Development

• June 2026: An approval was received by Obagi Medical from the U.S. FDA for saypha ChIQ, an injectable hyaluronic acid gel developed for improving cheek volume and correcting midface contour irregularities. The approval follows the launch of saypha MagIQ and the ALOHA program, which is collecting real-world insights on the use of MagIQ across diverse clinical settings. The introduction of ChIQ further strengthens the company’s presence in the dermal fillers industry and expands its range of aesthetic treatment options.

Further Report Findings

• In the regional forefront, Asia Pacific dominates the market for dermal fillers owing to a rise in luxury aesthetic clinics, growing beauty consciousness, and increasing influence of social media.
• Europe is estimated to register a CAGR of 5.37% over the forecast period. The region’s growth is driven by increasing preference for natural-looking results, a well-established dermal filler industry, and older adults in Europe seeking facial rejuvenation.
• Based on material, the hyaluronic acid segment accounted for the leading dermal fillers market share in 2025. The segment’s dominance is attributed to its wide range of applications, including wrinkle reduction, cheek contouring, lip enhancement, and restoration of facial volume.
• On the basis of gender, the female segment led in 2025 as women have traditionally shown stronger interest in cosmetic procedures and greater familiarity with injectable facial treatments.

Table of Segmentation